Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CPT1A | P50416 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rac-Etomoxir SCHEMBL15256787 | 1.00 | ABCB11 (1.00) | ABCB11LMNAMAPTMAPK1CPT1A | |
| SCHEMBL954683 | 1.00 | ABCB11 (1.00) | ABCB11LMNAMAPTMAPK1CPT1A | |
| Etomoxir SCHEMBL49075 | 1.00 | ABCB11 (1.00) | ABCB11LMNAMAPTMAPK1CPT1A | |
| Etomoxir SCHEMBL12813827 | 0.99 | MAPT (0.98) | ABCB11LMNAMAPTMAPK1CPT1A | |
| Etomoxir SCHEMBL5883664 | 0.99 | MAPT (0.98) | ABCB11LMNAMAPTMAPK1CPT1A | |
| Rac-Etomoxir SCHEMBL2141141 | 0.98 | MAPT (0.95) | ABCB11LMNAMAPTMAPK1CPT1A | |
| Etomoxir SCHEMBL22206060 | 0.93 | MAPT (0.87) | ABCB11LMNAMAPTMAPK1CPT1A | |
| SCHEMBL11294309 | 0.90 | LMNA (0.82) | ABCB11LMNAMAPTMAPK1CPT1A | |
| SCHEMBL14769764 | 0.90 | MAPT (0.82) | ABCB11LMNAMAPTMAPK1CPT1A | |
| SCHEMBL11288224 | 0.89 | MAPT (0.80) | ABCB11LMNAMAPTMAPK1HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200330400-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 AND FATTY ACID METABOLISM INHIBITORS | BERG LLC | 2020-10-22 | — | — | US | claimed |
| EP-2310003-B1 | INHIBITORS OF CARNITIN-PALMITOYL-TRANSFERASE-1 FOR THE TREATMENT AND PREVENTION OF DISORDERS CAUSED BY DELIPIDATION OF NEURAL TISSUE | META IQ APS (DK) | 2020-02-12 | — | — | EP | claimed |
| WO-2017161205-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 AND FATTY ACID METABOLISM INHIBITORS | BERG LLC (US) | 2017-09-21 | — | — | WO | claimed |
| EP-2445506-B1 | THE USE OF SPINOSYNS AND SPINOSYN COMPOSITIONS AGAINST DISEASES CAUSED BY PROTOZOANS, VIRAL INFECTIONS AND CANCER | ENTARCO SA (GR) | 2014-12-31 | — | — | EP | claimed |
| US-8741949-B2 | Inhibitors of carnitin-palmitoyl-tranferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue | META-IQ APS (DK) | 2014-06-03 | — | — | US | claimed |
| WO-2014018801-A1 | DIAGNOSIS AND TREATMENT OF CANCER USING DIFFERENTIALLY EXPRESSED STARVATION MARKERS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2014-01-30 | — | — | WO | claimed |
| WO-2013071029-A1 | METHODS AND PRODUCTS FOR GENERATING OILS | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2013-05-16 | — | — | WO | claimed |
| US-20130056683-A1 | COMPOSITIONS AND METHODS FOR PROMOTING FATTY ACID PRODUCTION IN PLANTS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-03-07 | — | — | US | claimed |
| WO-2012135632-A2 | METHODS OF TREATING A SUBJECT HAVING BEEN EXPOSED TO A CATASTROPHIC EVENT | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-10-04 | — | — | WO | claimed |
| EP-2486140-A2 | COMPOSITIONS AND METHODS FOR PROMOTING FATTY ACID PRODUCTION IN PLANTS | Regents of the University of Colorado (US) | 2012-08-15 | — | — | EP | claimed |
| EP-1275390-B1 | Medicament for treatment of heart failure | WOLF HORST P O (DE) | 2005-11-02 | — | — | EP | claimed |
| EP-1549398-A1 | INHIBITORS OF THE FATTY ACID OXIDATION FOR THE PROPHYLAXIS AND/OR THE TREATMENT OF CHRONIC AND/OR ATOPIC SKIN DISEASES | MediGene Aktiengesellschaft (DE) | 2005-07-06 | — | — | EP | claimed |
| US-20050004173-A1 | Inhibitors of fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction | MEDIGENE AG (DE) | 2005-01-06 | — | — | US | claimed |
| WO-2004026405-A1 | INHIBITORS OF THE FATTY ACID OXIDATION FOR THE PROPHYLAXIS AND/OR THE TREATMENT OF CHRONIC AND/OR ATOPIC SKIN DISEASES | MEDIGENE AKTIENGESELLSCHAFT (DE) | 2004-04-01 | — | — | WO | claimed |
| WO-2003037323-A2 | INHIBITORS OF THE FATTY ACID OXIDATION FOR PROPHYLAXIS AND TREATMENT OF DISEASES RELATED TO MITOCHONDRIAL DYSFUNCTION | MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie (DE) | 2003-05-08 | — | — | WO | claimed |
| US-5739159-A | Medicaments for the treatment of cardiac insufficiency | WOLF HORST (DE) | 1998-04-14 | — | — | US | claimed |
| EP-0231367-B1 | USE OF OXIRANCARBOXYLIC ACIDS FOR THE TREATMENT OF HYPERLIPEMIA | Wolf, Horst P.O., Dr. (DE) | 1991-07-24 | — | — | EP | claimed |
| US-4933365-A | ANTIFLAMMATORY AGENTS, ANTIALLERGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-06-12 | — | — | US | claimed |
| WO-1989005142-A1 | PHOSPHOLIPASE A2 INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-06-15 | — | — | WO | claimed |
| EP-0046590-B1 | PHEN(ALK)OXY-SUBSTITUTED OXIRANE-CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR USE AND DRUGS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1985-05-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004173-A1 | Inhibitors of fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction | CPT1A, CPT2, CPT1B | ABCB11 2356/4885LMNA 2830/4885MAPT 1990/4885 |
| US-20200330400-A1 | METHODS FOR THE TREATMENT OF CANCER USING COENZYME Q10 AND FATTY ACID METABOLISM INHIBITORS | CPT1B, CPT2, CPT1A | ABCB11 1461/4885LMNA 1667/4885MAPT 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.